Contraindicated. Coadministration of doravirine with a powerful CYP3A inducer may decrease doravirine plasma concentrations and/or effects. Potential for lack of virologic response and feasible resistance to doravirine.Observe Intently (one)pentobarbital will lower the extent or effect of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 me